{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:47:47Z","timestamp":1787060867467,"version":"build-2736575974"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 3","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To evaluate and compare the efficacy of topical nepafenac 0.1% administered three times daily versus nepafenac 0.3% administered once daily in patients with pseudoexfoliation syndrome (PEX) following routine cataract surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this retrospective cohort study, patients with PEX undergoing routine cataract surgery were divided into two groups for analysis. Group 1 received nepafenac 0.1% three times daily, while Group 2 received nepafenac 0.3% once daily. In both groups, nepafenac was started 1 day before surgery and continued for 2 weeks postoperatively. Anterior chamber flare was quantified using laser flare photometry (LFP), and central macular thickness (CMT) was measured using optical coherence tomography. Measurements were taken preoperatively, at 1 week, and at 6 weeks postoperatively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The study included 85 eyes from 85 patients, with 39 eyes in Group 1 and 46 eyes in Group 2. During the first postoperative week, Group 2 showed a significant reduction in LFP measurements (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.047) compared to Group 1. Notably, no significant difference was observed between the groups at the preoperative visit or at postoperative week 6. Comparisons of preoperative, 1-week, and 6-week postoperative CMT values also revealed no significant differences between the groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Nepafenac 0.3% used in routine cataract surgery in patients with PEX was shown to be at least as effective as nepafenac 0.1% in terms of aqueous flare and CMT. Aqueous flare values were more favorable with nepafenac 0.3% during the first week. In addition, the convenience of once-daily dosing may offer further advantages.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_2916_24","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T07:00:11Z","timestamp":1744873211000},"page":"S424-S427","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of topical nepafenac 0.1% and 0.3% on aqueous flare and macular thickness in patients with pseudoexfoliation following cataract surgery"],"prefix":"10.4103","volume":"73","author":[{"given":"Yusuf B","family":"Akbas","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Basaksehir Cam and Sakura City Hospital, University of Health Sciences, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahri O","family":"Aydin","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Basaksehir Cam and Sakura City Hospital, University of Health Sciences, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve","family":"Kelebek","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Basaksehir Cam and Sakura City Hospital, University of Health Sciences, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semih","family":"Cakmak","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Ceylan","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Basaksehir Cam and Sakura City Hospital, University of Health Sciences, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep Serikoglu","family":"Akbas","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Yildirim","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Basaksehir Cam and Sakura City Hospital, University of Health Sciences, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcin Kepez","family":"Yildiz","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Basaksehir Cam and Sakura City Hospital, University of Health Sciences, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"R1-20260422","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/BF00186513","article-title":"Blood-aqueous barrier in pseudoexfoliation syndrome: evaluation by immunohistochemical staining of endogenous albumin","volume":"234","author":"K\u00fcchle","year":"1996","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R2-20260422","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.jcrs.2009.03.011","article-title":"Pseudoexfoliation and the cataract surgeon: Preoperative, intraoperative, and postoperative issues related to intraocular pressure, cataract, and intraocular lenses","volume":"35","author":"Shingleton","year":"2009","journal-title":"J Cataract Refract Surg"},{"key":"R3-20260422","first-page":"188","article-title":"Investigation of eNOS G894T gene polymorphism in patients with pseudoexfoliation syndrome: A preliminary study","volume":"7","author":"Dursun","year":"2022","journal-title":"Beyoglu Eye J"},{"key":"R4-20260422","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/bjo.67.4.249","article-title":"Fluorescein angiography and fluorophotometry of the iris in pseudoexfoliation of the lens capsule","volume":"67","author":"Brooks","year":"1983","journal-title":"Br J Ophthalmol"},{"key":"R5-20260422","first-page":"578","article-title":"Tyndallometry with the laser flare cell meter and biochemical protein determination in the aqueous humor of eyes with pseudoexfoliation syndrome","volume":"91","author":"K\u00fcchle","year":"1994","journal-title":"Ophthalmologe"},{"key":"R6-20260422","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/sj.eye.6702602","article-title":"The spectrum of iris angiography abnormalities in pseudoexfoliation syndrome","volume":"22","author":"Parodi","year":"2008","journal-title":"Eye"},{"key":"R7-20260422","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1159\/000027460","article-title":"Corneal endothelial changes and aqueous flare intensity in pseudoexfoliation syndrome","volume":"213","author":"Wang","year":"1999","journal-title":"Ophthalmologica"},{"key":"R8-20260422","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4274\/tjo.galenos.2018.10734","article-title":"Role of oxidative stress in pseudoexfoliation syndrome and pseudoexfoliation glaucoma","volume":"49","author":"Yaz","year":"2019","journal-title":"Turk J Ophthalmol"},{"key":"R9-20260422","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1001\/archopht.117.6.733","article-title":"Quantification of aqueous flare after phacoemulsification with intraocular lens implantation in eyes with pseudoexfoliation syndrome","volume":"117","author":"Schumacher","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"R10-20260422","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2415-12-13","article-title":"Outcome of phacoemulsification in patients with and without pseudoexfoliation syndrome in Kashmir","volume":"12","author":"Sufi","year":"2012","journal-title":"BMC Ophthalmol"},{"key":"R11-20260422","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.survophthal.2009.07.005","article-title":"Nonsteroidal anti-inflammatory drugs in ophthalmology","volume":"55","author":"Kim","year":"2010","journal-title":"Surv Ophthalmol"},{"key":"R12-20260422","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000320078","article-title":"Postsurgical cystoid macular edema","volume":"47","author":"Loewenstein","year":"2010","journal-title":"Macular Edema"},{"key":"R13-20260422","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1016\/S0886-3350(99)00196-0","article-title":"Cystoid macular edema after phacoemulsification: Relationship to blood\u2013aqueous barrier damage and visual acuity","volume":"25","author":"Ursell","year":"1999","journal-title":"J Cataract Refract Surg"},{"key":"R14-20260422","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"R15-20260422","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.ajo.2008.06.004","article-title":"Interobserver agreement in grading activity and site of inflammation in eyes of patients with uveitis","volume":"146","author":"Kempen","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R16-20260422","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.survophthal.2004.10.004","article-title":"Laser flare-cell photometry: Methodology and clinical applications","volume":"50","author":"Ladas","year":"2005","journal-title":"Surv Ophthalmol"},{"key":"R17-20260422","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jcrs.2006.08.043","article-title":"Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery","volume":"33","author":"Lane","year":"2007","journal-title":"J Cataract Refract Surg"},{"key":"R18-20260422","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1023\/A:1007001131987","article-title":"Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers","volume":"24","author":"Ke","year":"2000","journal-title":"Inflammation"},{"key":"R19-20260422","first-page":"39","article-title":"Cyclooxygenase and lipoxygenase pathways in anterior uvea and conjunctiva","volume":"312","author":"Kulkarni","year":"1989","journal-title":"Prog Clin Biol Res"},{"key":"R20-20260422","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/j.jcrs.2015.10.061","article-title":"Effect of topical ketorolac 0.4%, nepafenac 0.1%, and bromfenac 0.09% on postoperative inflammation using laser flare photometry in patients having phacoemulsification","volume":"41","author":"Sahu","year":"2015","journal-title":"J Cataract Refract Surg"},{"key":"R21-20260422","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s12325-011-0080-7","article-title":"Prostaglandin E 2 inhibition of ketorolac 0.45%, bromfenac 0.09%, and nepafenac 0.1% in patients undergoing phacoemulsification","volume":"28","author":"Bucci","year":"2011","journal-title":"Adv Ther"},{"key":"R22-20260422","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jcrs.2013.07.042","article-title":"Once-daily nepafenac ophthalmic suspension 0.3% to prevent and treat ocular inflammation and pain after cataract surgery: Phase 3 study","volume":"40","author":"Modi","year":"2014","journal-title":"J Cataract Refract Surg"},{"key":"R23-20260422","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4103\/ijo.IJO_2401_21","article-title":"Comparison of once daily dose of 0.3% nepafenac alone and three times dose of 0.1% nepafenac alone in pain and inflammation control after phacoemulsification","volume":"70","author":"Bardoloi","year":"2022","journal-title":"Indian J Ophthalmol"},{"key":"R24-20260422","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.jcrs.2006.04.009","article-title":"Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: Pharmacokinetic-response curve","volume":"32","author":"Donnenfeld","year":"2006","journal-title":"J Cataract Refract Surg"},{"key":"R25-20260422","doi-asserted-by":"crossref","first-page":"101463.","DOI":"10.1016\/j.eclinm.2022.101463","article-title":"Prophylactic interventions for preventing macular edema after cataract surgery in patients with diabetes: A Bayesian network meta-analysis of randomized controlled trials","volume":"49","author":"Zhang","year":"2022","journal-title":"EClinicalMedicine"},{"key":"R26-20260422","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jcrs.2016.06.006","article-title":"Cataract surgery and nonsteroidal antiinflammatory drugs","volume":"42","author":"Hoffman","year":"2016","journal-title":"J Cataract Refract Surg"},{"key":"R27-20260422","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10792-016-0169-8","article-title":"Anterior chamber aqueous flare, pseudoexfoliation syndrome, and glaucoma","volume":"36","author":"Kahloun","year":"2016","journal-title":"Int Ophthalmology"},{"key":"R28-20260422","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jcrs.2016.04.031","article-title":"Bromfenac ophthalmic solution 0.09% as an adjunctive therapy to topical steroids after cataract surgery in pseudoexfoliation syndrome","volume":"42","author":"Coassin","year":"2016","journal-title":"J Cataract Refract Surg"},{"key":"R29-20260422","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jcrs.2018.01.029","article-title":"European multicenter trial of the prevention of cystoid macular edema after cataract surgery in nondiabetics: ESCRS PREMED study report 1","volume":"44","author":"Wielders","year":"2018","journal-title":"J Cataract Refract Surg"},{"key":"R30-20260422","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1080\/02713683.2019.1701686","article-title":"Anti-inflammatory medication of cataract surgery in Pseudoexfoliation syndrome\u2013NSAID is needed","volume":"45","author":"Ilveskoski","year":"2020","journal-title":"Curr Eye Res"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_2916_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:55:21Z","timestamp":1786647321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_2916_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":30,"journal-issue":{"issue":"Suppl 3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_2916_24","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"assertion":[{"value":"2024-12-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}